- Home
- BTM vs UNCY Comparison
BTM vs UNCY Comparison
Compare BTM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTM | UNCY |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 121.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTM | UNCY |
|---|---|---|
| Price | $1.33 | $5.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.25 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 1.5M | 394.5K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $635,643,000.00 | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.24 | ★ N/A |
| Revenue Growth | ★ 8.61 | N/A |
| 52 Week Low | $0.93 | $3.71 |
| 52 Week High | $6.88 | $11.00 |
Technical Indicators
Market Signals| Indicator | BTM | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 50.86 |
| Support Level | $1.29 | $6.31 |
| Resistance Level | $1.69 | $6.95 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 8.75 | 28.23 |
Price Performance
Historical ComparisonAbout BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.